Want to see IN:TARSONS full AI Analyst Report?
Tarsons Products Limited (TARSONS) AI Stock Analysis
Top Page
Tarsons Products Limited
(NSE:TARSONS)
The score is held back primarily by weakening profitability, rising debt, and persistently negative free cash flow, alongside a very high P/E valuation. Technicals are moderately supportive with price above major moving averages, but mixed momentum (negative MACD) limits the uplift.
Tarsons Products Limited (TARSONS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 16.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 20.02K
- Price to Earnings (P/E)
- 139.2
- Beta (1Y)
- 1.02
- Revenue Growth
- 10.63%
- EPS Growth
- -59.63%
- Country
- India
- Employees
- 1,108
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Tarsons Products Limited Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features dis...
Tarsons Products Limited Financial Statement Overview
Summary
Financials show pressure despite revenue recovery: earnings power and margins have deteriorated versus 2021–2023, leverage has risen meaningfully since 2023, and free cash flow has been persistently negative (2022–2026) even though operating cash flow is positive.
Income Statement
48NeutralBalance Sheet
55NeutralCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.23B | 3.92B | 2.96B | 2.83B | 3.01B |
| Gross Profit | 1.11B | 1.12B | 1.35B | 985.42M | 1.25B | 1.49B |
| EBITDA | 1.32B | 1.18B | 1.27B | 1.11B | 1.42B | 1.61B |
| Net Income | 110.95M | 143.22M | 297.70M | 426.40M | 807.14M | 1.01B |
Balance Sheet | ||||||
| Total Assets | 0 | 11.86B | 10.80B | 9.72B | 7.26B | 5.44B |
| Cash, Cash Equivalents and Short-Term Investments | 252.56M | 252.56M | 256.52M | 226.11M | 590.58M | 774.42M |
| Total Debt | 0 | 3.93B | 3.39B | 2.69B | 1.11B | 216.65M |
| Total Liabilities | -6.35B | 5.51B | 4.50B | 3.59B | 1.56B | 543.96M |
| Stockholders Equity | 6.35B | 6.35B | 6.30B | 6.13B | 5.69B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | -267.75M | -71.03M | -550.87M | -816.28M | -1.14B | -485.02M |
| Operating Cash Flow | 444.51M | 1.18B | 966.20M | 1.03B | 755.99M | 834.67M |
| Investing Cash Flow | -783.05M | -1.30B | -1.47B | -2.85B | -1.79B | -1.38B |
| Financing Cash Flow | 321.34M | 89.33M | 578.12M | 1.36B | 845.61M | 1.30B |
Tarsons Products Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Negative. The current price of 291.75 is below the 20-day moving average (MA) of 319.04, below the 50-day MA of 325.78, and above the 200-day MA of 255.41, indicating a neutral trend. The MACD of -8.02 indicates Positive momentum. The RSI at 36.90 is Neutral, neither overbought nor oversold. The STOCH value of 20.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TARSONS.
Tarsons Products Limited Peers Comparison
Overall Rating
IN:VIMTALABS69Neutral
IN:ZIMLAB60Neutral
IN:POLYMED59Neutral
IN:FISCHER57.7Neutral- IN:TARSONS47Neutral
IN:KREBSBIO44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:VIMTALABS | 69Neutral | INR 21.67B | 27.15 | ― | 0.41% | 14.22% | 7.17% |
| IN:ZIMLAB | 60Neutral | INR 7.32B | 166.21 | ― | ― | 7.55% | -57.19% |
| IN:POLYMED | 59Neutral | INR 146.76B | 46.62 | ― | 0.24% | 18.31% | -12.86% |
| IN:FISCHER | 58Neutral | INR 16.20B | 54.14 | ― | 0.20% | 195.95% | 1526.86% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:TARSONS | 47Neutral | INR 15.52B | 139.23 | ― | ― | 10.63% | -59.63% |
| IN:KREBSBIO | 44Neutral | INR 1.26B | -8.65 | ― | ― | -1.32% | 51.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:TARSONS | Tarsons Products Limited | 291.75 | 2.70 | 0.93% | |
| IN:KREBSBIO | Krebs Biochemicals & Industries Ltd. | 58.36 | -10.84 | -15.66% | |
| IN:POLYMED | Poly Medicure Limited | 1447.90 | -463.33 | -24.24% | |
| IN:VIMTALABS | Vimta Labs Limited | 484.85 | -194.79 | -28.66% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 136.45 | 63.40 | 86.79% | |
| IN:FISCHER | Fischer Medical Ventures Ltd | 24.75 | -82.29 | -76.88% |
Tarsons Products Limited Corporate Events
Tarsons Products Convenes 43rd AGM via Virtual Platform with Strong Shareholder Turnout
Tarsons Products Limited held its 43rd Annual General Meeting on September 24, 2026, via video conferencing in compliance with MCA and SEBI circulars and applicable listing regulations. The meeting saw participation from key members of the board, sen...
Tarsons Schedules Virtual Analyst Meet with Arihant Capital
Tarsons Products Limited has notified stock exchanges that its officials will participate in a virtual group meeting hosted by Arihant Capital on September 30, 2026, between 5:00 p.m. and 6:00 p.m. IST. The interaction is aimed at analysts and instit...
Tarsons Clarifies Share Volume Surge, Affirms Full Regulatory Compliance
Tarsons Products Limited, an ISO-certified manufacturer in the laboratory and life-sciences consumables space, is headquartered in Kolkata and listed on the National Stock Exchange of India under the symbol TARSONS. The company serves institutional a...
Tarsons Products Publishes Q1 FY27 Investor Presentation for Market Disclosure
Tarsons Products Limited has released an investor presentation detailing its financial results for the quarter ended June 30, 2026, and submitted the same to both the BSE and NSE in line with SEBI disclosure regulations. The document, prepared under...
Tarsons Posts Q1 FY27 Results and Sets Date for 43rd AGM
Tarsons Products Limited reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as approved by its board of directors in a meeting held on August 10, 2026. The results, accompanied by a limited revie...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 22, 2026